Companies / OCC

ORTHOCELL LIMITED

ASX:OCCPharmaceuticals, Biotechnology & Life Sciences
272.3M shares on issueASX (delayed) · as of 28 July 2026$0.71price · delayed$193.4Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 30% in 24 months; 4 cash raises in 24 months

Cash runway1.7 quarters of funding
Share-count growth (24m)30.1%
Raise cadence (24m)4 cash raises
Options & rights overhang12.1% of shares
In-the-money supply6.8% of shares
Pending proposed issuesnone

ORTHOCELL LIMITED's ordinary share count grew 30.1% between March 2024 and July 2026 to 272M shares. The company raised capital four times in that period for total proceeds of A$77.4M, most recently a A$30.0M placement in October 2025. Options and rights on issue could convert into 33M new shares, equal to 12.1% of the current share count, of which 7% are in the money at the current share price; the nearest expiry is April 2027. At the June 2026 quarter the company reported A$7.9M in cash, representing about 1.7 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
12.1%
Max option dilution
6.8%
ITM option dilution
2
Raises · last 12 months
1.7 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 272.3M per ASX (delayed) (28 July 2026).
246.2M255.8M265.4MDec 24Sept 25July 26Cash raise · 14 Oct 2025Cash raise · 14 Oct 2025Cash raise · 10 June 2025

Cash runway

1.7 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$7.9M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
20 July 20262A · quoted issueOCC : ORDINARY FULLY PAID272.3MAppendix 2A
17 July 20263G · unquotedOCC : ORDINARY FULLY PAID272.3MAppendix 3G
17 July 20263G · unquotedORDINARY FULLY PAID272.3MAppendix 3G
17 July 20262A · quoted issueOCC : ORDINARY FULLY PAID272.3MAppendix 2A
16 July 20263H · cancellationOCC : ORDINARY FULLY PAID272.3MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

4 cash raises in the last 24 months · 2 in the last 12 months

$30.0M
Placement
14 Oct 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

12.1%
Total overhang · of current shares
6.8%
In the money · at current price
32.9M
Potential new shares
Apr 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
20 July 2026John Van Der WielenBuy15—$12k3Y notice
17 July 2026John Van Der WielenBuy23k4.0M$18k3Y notice
17 July 2026Dr Ravi ThadhaniBuy17k3.0M$13k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

20 July 2026Appendix 3Y - John Van Der Wielen
20 July 2026Application for quotation of securities - OCC
17 July 2026Appendix 3Y x 4
17 July 2026Application for quotation of securities - OCC
17 July 2026Notification regarding unquoted securities - OCC
17 July 2026Notification regarding unquoted securities - OCC
17 July 2026Option Terms and Conditions
17 July 2026Proposed issue of securities - OCC
16 July 2026Notification of cessation of securities - OCC
13 July 2026$PQ4 FY26 ASX Investor Presentation
12 July 2026$PQuarterly Activity Report & Appendix 4C
5 July 2026Orthocell Investor Webinar Details
2 July 2026$POrthocell Appoints Thailand Distributor for Remplir
29 June 2026Clinical Outcomes See Expanded Use of Remplir in the Ukraine
14 May 2026Cleansing Notice
14 May 2026Application for quotation of securities - OCC
5 May 2026Cleansing Notice
5 May 2026Application for quotation of securities - OCC
3 May 2026Appendix 3Y - Michael McNulty
3 May 2026Appendix 3Y - John Van Der Wielen

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.